SCHEMBL20067086

SCHEMBL20067086

Nc1nccc(-c2cccc(C(=O)CO)c2)c1[N+](=O)[O-]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
PRKCI P41743 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
PSMD14 O00487 1/20 0.38
PRKACA P17612 1/20 0.38
CASP6 P55212 1/20 0.38
DGAT2 Q96PD7 1/20 0.38
DYRK1A Q13627 1/20 0.36
FYN P06241 1/20 0.35
KMO O15229 1/20 0.35
MAP4K4 O95819 1/20 0.35
MAPT P10636 3/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ERCC5 P28715 1/20 0.35
FEN1 P39748 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MITF O75030 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18131869 0.82 ERN1 (0.46) KMT2AMEN1MAPTKDM4E
SCHEMBL1840937 0.79 MEN1 (0.48) ALDH1A1KMT2AMEN1PSMD14PRKACA
SCHEMBL4934653 0.77 KDM4E (0.56) ALDH1A1KMT2AMEN1MAP4K4GAA
SCHEMBL4937390 0.74 RAB9A (0.46) KMT2AMEN1DYRK1AFYNMAP4K4
SCHEMBL17555611 0.73 MAPT (0.44) KMT2AMEN1PSMD14PRKACACASP6
SCHEMBL18131070 0.71 HTT (0.46) ALDH1A1KMT2AMEN1PSMD14PRKACA
SCHEMBL19588688 0.70 BRD4 (0.45) HTT
SCHEMBL17555750 0.68 HTT (0.48) PRKCIKMT2AMEN1PSMD14PRKACA
SCHEMBL4930996 0.68 DYRK1A (0.44) ALDH1A1KMT2AMEN1DYRK1AMAP4K4
SCHEMBL1840418 0.68 MAP4K4 (0.40) KMT2AMEN1MAP4K4MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105518-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105518-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF NGFR, NTRK2, NGF ALDH1A1 4433/4885PRKCI 1171/4885KMT2A 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.